Proton pump inhibitors: New drugs and indications

American Family Physician

Volumn 53, Issue 1, 1996, Pages 285-292

  Mears, James M ^a   Kaplan, Barbara ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYTOCHROME P450; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG PROTEIN BINDING; ENZYME INHIBITION; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; LIVER TOXICITY; PEPTIC ULCER; PROTON TRANSPORT; SKIN TOXICITY; STOMACH ACID SECRETION; ZOLLINGER ELLISON SYNDROME;

EID: 0030044512     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989;97:827-36.
2. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Aliment Pharmacol Ther 1988;2:13-32.
3. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993;7(Suppl 1):41-50.
4. Sachs G, Shin JM, Besancon M, Prinz C. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993;7(Suppl 1):4-12.
5. Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992;44:225-50.
6. Festen HP, Thijs JC, Lamers CB, Jansen JM, Pals G, Frants RR, et al. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology 1984;87:1030-4.
7. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy 1993;13:46-59.
8. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991;3:315-20.
9. Pue MA, Laroche J, Meineke I, de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993;44:575-8.
10. Kastrup EK, Olin BR, eds. Facts and comparisons. St. Louis: Facts and Comparisons, 1991.
11. Muller P, Simon B, Khalil H, Luhmann R, Leucht U, Schneider A. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 1992;30:771-5.
12. Solvell L. The clinical safety of omeprazole. Digestion 1990;47(Suppl l):59-63.
13. Simon TJ, Bradstreet DC. Comparative tolerability profile of omeprazole in clinical trials. Dig Dis Sci 1991;35:1384-9.
14. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992;6:399-406.
15. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (Vitamin B12). Ann Intern Med 1994;120:211-5.
16. Drug interaction facts. In: Facts and comparisons. St. Louis: Facts and Comparisons, 1995.
17. Cavanaugh JH, Winters EP, Cohen A, Locke CS, Braeckman R. Lack of effect of lansoprazole on steady state warfarin metabolism [Abstract]. Gastroenterology 1991;5:100.
18. Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, Van Ganse E. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992;52:458-63.
19. Granneman G, Winters EP, Locke CS, Leese PT, Karol MD, et al. Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics [Abstract]. Gastroenterology 1991;5:100.
20. Robinson M, Decktor DL, Maton PN, Sabesin S, Roufail W, Kogut D, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993;7:67-73.
21. Bardhan KD, Bianchi-Porro G, Bose K, Daly M, Hinchliffe RF, Jonsson E, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterology 1986;8:408-13.
22. McFarland RJ, Bateson MC, Green JR, O'Donoghue DP, Dronfield MW, Keeling PW, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990;98:278-83.
23. Archambult AP, Pare P, Bailey RJ, Navert H, Williams CN, Freeman HJ, et al. Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. Gastroenterol 1988;94(5 Pt 1):1130-4.
24. Joelson S, Joelson IB, Lundborg P, Walan A, Wallander MA. Safety experience from long-term treatment with omeprazole. Digestion 1992;51 (Suppl 1):93-101 [Published erratum appears in Digestion 1992;53:213].
25. Brunner GH, Lamberts R, Creutzfeldt W. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 1990;47(Suppl 1):64-8.
26. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
27. Berlin RG. Omeprazole. Gastrin and gastric endocrine cell data from clinical studies. Dig Dis Sci 1991;36:129-36.
28. Freston JW. Clinical significance of hypergastrin-aenemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 1992;51 (Suppl 1):102-14.
29. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Rev Infect Dis 1990;12 (Suppl 1):S87-93.
30. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990;4:25-33.
31. Walan A, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
32. Inatomi N, Nagaya H, Takami K, Shino A, Satoh H. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Japanese J Pharmacol 1991;55:437-51.
33. Okabe S, Miyake H, Awane Y. Cytoprotective effects of NC-1300 and omeprazole on Hcl ethanol-induced gastric lesions in rats. Japanese J Pharmacol 1986;42:123-33.
34. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994;39:97-103.
35. Hanauer G, Graf U, Meissner T. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/ SK&F 96022) compared to other antiulcer drugs. Methods Find Exp Clin Pharmacol 1991;13:63-7.
36. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993;7(Suppl 1):13-24.
37. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993;196(Suppl):12-6.
38. Beil W, Staar U, Sewing KF. Pantoprazole: a novel H+/K(+) -ATPase inhibitor with an improved pH stability. Eur J Pharmacol 1992;218:265-71.